Thursday, September 18, 2025

Latest

Shroom Boom! Has Michael Frank Brought Revive Back from the Dead?

Yesterday Revive Therapeutics (CSE: RVV) increased 81.8% from 5.5c to 10c on 4.1M shares traded. Presumably, RVV is beginning to take notice, thanks to the listing of other psilocybin issuers in Canada including MindMed (NEO: MMED) and Champignon Brands (CSE: SHRM).

Prior to the recent run up, it has been a challenging couple of years for RVV shareholders which saw the stock decline from a high of 48c in early 2018 to a low of 2.5c prior to the recent run back to 10c.

In late 2019, Revive announced management changes which included Michael Frank stepping in as CEO. Shortly afterwards the company announced the acquisition of Psilocin Pharma Corp.

Psilocin Pharma focuses on intellectual property covering methods of production of psilocybin based formulations. They have developed 6 formulations to date ranging from capsules, sprays and breath strips. The precisely dosed formulations work with both natural and synthetically derived psilocybin which will be targeted for clinical research and subject to eventually FDA approval in the treatment of depression, anxiety, bi-polar disorder, bulimia & anorexia nervosa, etc.  

The companies core mandate outside of the recently announced acquisition is to focus on the research, development and commercialization of novel cannabinoid-based and life sciences products. Revive’s cannabinoid pharmaceutical portfolio focuses on rare inflammatory areas such as liver disease. The company has been granted FDA orphan drug status designation for the use of CBD to treat auto-immune hepatitis (liver disease) and FDA orphan drug status designation for the use of CBD to treat ischemia and reperfusion injury from organ transplantation. They are expected to take a similar approach with Psilocin Pharma.

In a corporate update on February 16th, 2020, Revive announced they are currently in the process of preparing their Investigational New Drug (IND) application for submission to the U.S. Food and Drug Administration (FDA) for CBD in the treatment of liver disease.

In the announcement newly appointed CEO Michael Frank said, “Revive is focused on advancing its cannabinoid-based product pipeline towards human clinical studies with our lead program being CBD in the treatment of AIH (auto-immune hepatitis), a rare liver disease that represents a large market opportunity globally.” 

Yesterday Revive Therapeutics closed up 81.18% on the day to $0.10.


FULL DISCLOSURE: Revive Therapeutics is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Revive Therapeutics on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

The Pure Silver Set Up! | Joaquin Marias – Argenta Silver Corp

Why $30,000 Gold Isn’t Crazy! | Simon Marcotte – Northern Superior

2026 Could Be Gold’s Biggest Year Yet!? | Ryan King – Equinox Gold

Recommended

Canadian Copper Secures $8 Million Lead Order From Ocean Partners As Part Of Larger Funding Round

Northern Superior Expands Philibert With 350 Metre Step Out Testing 1.10 g/t Gold Over 25.5 Metres

Related News

Revive Files IND Application With FDA For Phase 3 Clinical Study For COVID-19 Treatment

Revive Therapeutics (CSE: RVV) announced after the bell today that it has officially filed its...

Tuesday, June 30, 2020, 07:18:46 PM

Revive Sees Expanded Access Protocol Approved For Compassionate Use Of Bucillamine

Revive Therapeutics (CSE: RVV) this morning announced that it has received approval from the Independent...

Wednesday, September 16, 2020, 08:23:03 AM

Australia Becomes First to Reclassify MDMA and Psilocybin As Medicine for Specific Uses

Australia has become the first country in the world to re-classify the psychedelic substances psilocybin...

Monday, February 13, 2023, 03:47:00 PM

Revive Therapeutics Signs MOU With Attwill Medical, Manufacturer For Vaxart, For Phase 3 Clinical Trials

Revive Therapeutics (CSE: RVV) (OTC: RVVTF) is one step closer to conducting its phase 3...

Friday, August 14, 2020, 08:50:35 AM

Revive Therapeutics Reports Successful Results Using Psilocybin To Treat Traumatic Brain Injury

Revive Therapeutics (CSE: RVV) this morning revealed that it has received positive results for a...

Friday, March 19, 2021, 07:47:09 AM